Your browser doesn't support javascript.
loading
Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.
Jomrich, Gerd; Kollmann, Dagmar; Ramazanova, Dariga; Ristl, Robin; Grose, Richard P; Ilhan-Mutlu, Aysegül; Preusser, Matthias; Fassnacht, Christina; Tsai, Yi-Chien; Guenova, Emmanuella; Schoppmann, Sebastian F.
Afiliación
  • Jomrich G; Department of Surgery, Comprehensive Cancer Center Vienna, Upper-GI-Service, GET-Unit, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
  • Kollmann D; Department of Surgery, Comprehensive Cancer Center Vienna, Upper-GI-Service, GET-Unit, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
  • Ramazanova D; Section for Medical Statistics (IMS), Center of Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
  • Ristl R; Section for Medical Statistics (IMS), Center of Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
  • Grose RP; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, United Kingdom.
  • Ilhan-Mutlu A; Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, GET-Unit, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
  • Preusser M; Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, GET-Unit, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
  • Fassnacht C; Department of Dermatology, University Hospital Zurich and Faculty of Medicine, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland; Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, Av de Beaumont 29, CH-1011,
  • Tsai YC; Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, Av de Beaumont 29, CH-1011, Lausanne, Switzerland.
  • Guenova E; Department of Dermatology, University Hospital Zurich and Faculty of Medicine, University of Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland; Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, Av de Beaumont 29, CH-1011,
  • Schoppmann SF; Department of Surgery, Comprehensive Cancer Center Vienna, Upper-GI-Service, GET-Unit, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. Electronic address: sebastian.schoppmann@meduniwien.ac.at.
Eur J Surg Oncol ; 48(2): 383-390, 2022 Feb.
Article en En | MEDLINE | ID: mdl-34404561
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Linfocitos Infiltrantes de Tumor / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Austria
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Linfocitos Infiltrantes de Tumor / Antígeno B7-H1 / Receptor de Muerte Celular Programada 1 Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Austria